1 School of Nursing, Columbia University , New York, New York.
2 Appalachian State University , Boone, North Carolina, Visiting Nurse Service of New York, New York, New York.
J Palliat Med. 2018 Nov;21(11):1651-1661. doi: 10.1089/jpm.2018.0141. Epub 2018 Aug 21.
The Palliative Performance Scale (PPS) has been widely used for survival prediction among patients with cancer; however, few studies have reviewed PPS scores in heterogeneous palliative care populations across multiple care settings.
The aim of this systematic review was to determine how the PPS tool has been used to estimate survival at the end of life.
This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Embase, and the Cochrane Library were searched for the existing literature published from 2008 to 2017. We synthesized study characteristics, the PPS scores at baseline, and primary outcomes, and explored differences in survival estimates by diagnosis. The quality of the studies was assessed using the Good ReseArch for Comparative Effectiveness (GRACE) checklist.
Seventeen studies were included in this review (nine with cancer and eight with mixed diagnoses). All included studies reported that the PPS exhibited a significant association with survival. Survival estimates ranged from 1 to 3 days for patients with PPS scores of 10% compared with 5 to 36 days for those with scores of 30%. The categorical cut-points for the PPS scores were not consistently reported across studies.
This review provides a broad overview on the prognostic value of the PPS tool for survival among multiple patient populations across care settings. Consistent reporting of PPS scores would facilitate the comparison of survival estimates across end-of-life diagnoses.
姑息治疗表现量表(PPS)已广泛用于癌症患者的生存预测;然而,很少有研究综合多个照护环境下的姑息治疗患者群体的 PPS 评分进行综述。
本系统综述的目的是确定 PPS 工具如何用于估计生命终末期的生存。
本综述遵循系统评价和荟萃分析的首选报告项目指南。检索了 2008 年至 2017 年发表的现有文献,包括 PubMed、Embase 和 Cochrane 图书馆。我们综合了研究特征、基线 PPS 评分和主要结局,并通过诊断探讨了生存估计的差异。使用 Good ReseArch for Comparative Effectiveness (GRACE) 清单评估研究质量。
本综述共纳入了 17 项研究(9 项为癌症患者,8 项为混合诊断患者)。所有纳入的研究均报告 PPS 与生存显著相关。PPS 评分为 10%的患者的生存估计为 1 至 3 天,而评分为 30%的患者的生存估计为 5 至 36 天。研究之间并未一致报告 PPS 评分的分类截断点。
本综述广泛概述了 PPS 工具在多个照护环境下的姑息治疗患者群体中的生存预测价值。一致报告 PPS 评分将有助于比较不同临终诊断的生存估计。